Coherus Biosciences Logo
US19249H1032
A12ETZ
CHRS

Coherus Biosciences

Wczytywanie kursów wyceny...

Prognoza

Średnia cena docelowa analityków wynosi 5,49 € (+1344,74%). Mediana wynosi 5,47 € (+1339,47%).

Kupuj
  14
Trzymaj
  3
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Coherus Oncology will use LOQTORZI revenues to finance pipeline with Tagmokitug and Casdozokitug

    Coherus Oncology follows a two‑pillar strategy: LOQTORZI is expected to deliver near‑term revenue to fund development of the immune‑resistance–focused programs Tagmokitug (CCR8 antibody) and Casdozokitug (IL‑27 antagonist). Management projects LOQTORZI will reach an annualized revenue of about $175 million by 2026 and quarterly sales of $15 million (2026) and $30–35 million by the end of 2027, which should cover operating costs. Tagmokitug is regarded as the lead candidate with several data readouts from late 2025 through 2026, including full data from the head‑and‑neck study in October 2025. Casdozokitug showed early efficacy in hepatocellular carcinoma (ORR 38%, CR 17%) and is in a randomized trial with data expected by the end of 2025. » Więcej na de.investing.com


  • Coherus BioSciences misses Q1 2026 revenue forecast, stock climbs in after-hours

    Coherus BioSciences reported Q1 2026 revenue of $12.31 million, missing the $14.43 million estimate, while EPS of -$0.25 matched expectations. Despite the revenue shortfall, the stock rose 11.43% in after-hours trading to $1.89, driven by optimism about growth opportunities and strategic initiatives. Lead product LOQTORZI achieved 61% year‑over‑year revenue growth; management expects a weather‑related recovery in Q2 and targets quarterly revenues of $15 million by the end of 2026 and $30–35 million for 2027. » Więcej na de.investing.com


  • Coherus BioSciences shifts strategic focus to oncology and immune resistance

    Under CEO Dennis Lanfear, Coherus BioSciences is making a strategic shift to oncology with an emphasis on immune resistance and is strengthening its pipeline through the acquisition of Surface Oncology and the sale of biosimilar assets. The sale proceeds from UDENYCA generated an upfront payment of $483 million plus expected follow‑on payments, and the company raised an additional $50 million. LOQTORZI revenue rose to $40.8 million in 2025 and is expected to cover sales expenses by 2026 and core operating costs by 2027; clinical data on Tagmokitug and Casdozokitug are considered promising. Coherus is expanding its sales force, pursuing partnerships outside the U.S., and is targeting a mid‑term market share of 70% for LOQTORZI. » Więcej na de.investing.com


  • Coherus BioSciences shifts strategy to oncology and strengthens balance sheet

    At the TD Cowen conference Coherus BioSciences announced a strategic realignment toward oncology, highlighted its improved financial position and the development of an innovative pipeline. The company reduced debt from $480 million to $3.7 million, received $250 million from the sale of its biosimilar business and reported LOQTORZI revenues of $38 million (2025); it is targeting a $175 million run rate by 2028. Coherus aims for cash‑flow breakeven at about $30 million in quarterly LOQTORZI sales, plans partnerships for Tagmokitug and Casdozokitug, and expects initial phase‑2 data for Casdozokitug midyear with a reported complete response rate of 17% in liver cancer. » Więcej na de.investing.com


  • Coherus Oncology files prospectus for stock offering up to $64.9 million

    Coherus Oncology has filed a prospectus supplement to its existing sales agreement with TD Cowen under which common shares may be offered and sold at an aggregate offering price of up to $64,880,054. The sales agreement originally dated November 8, 2022, has been amended several times; sales will be made from time to time through TD Cowen. A legal opinion from Latham & Watkins on the validity of the issuance was filed as an exhibit to the registration statement. The common shares are listed on the Nasdaq Global Market. » Więcej na de.investing.com

Dane finansowe spółki

W ostatnim kwartale Coherus Biosciences osiągnęła przychody w wysokości 12,6 mln € i zysk netto w wysokości -34,73 mln €
(EUR) wrzesień 2026
YoY
Przychody 12,6 mln 27,81%
Zysk brutto 8,99 mln 53,24%
Zysk netto -34,73 mln 16,07%
EBITDA -31,11 mln 11,44%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
58,02 mln €
Liczba akcji
154,54 mln
Maksimum/minimum z 52 tygodni
2,39 € - 0,37 €
Dywidendy Nie
Beta
1,03
C/Z (PE Ratio)
-0,42
PEG (PEG Ratio)
-0,01
C/WK (PB Ratio)
2,53
C/S (PS Ratio)
1,19

Profil spółki

Coherus BioSciences, Inc., firma biofarmaceutyczna, koncentruje się na rynku biopodobnych leków i immunoonkologii, działając przede wszystkim w Stanach Zjednoczonych. Spółka wprowadza na rynek UDENYCA, biopodobny lek do Neulasty, długo działającego czynnika stymulującego tworzenie kolonii granulocytów, w Stanach Zjednoczonych. W jej portfelu produktów rozwojowych znajdują się biopodobne odpowiedniki Humiry, Avastinu i Lucentisu. Spółka rozwija również Toripalimab, nowatorskie przeciwciało anty-PD-1 do leczenia drugiej linii czerniaka w Chinach; biopodobny bewacyzumab; oraz CHS-1420, kandydat na produkt anty-TNF, jako biopodobny adalimumab; biopodobny ranibizumab. Coherus BioSciences, Inc. posiada umowy licencyjne z Selexis SA, AbbVie, Inc., Pfizer, Inc., Bioeq AG, Innovent Biologics (Suzhou) Co., Ltd. oraz Junshi Biosciences. Spółka wcześniej funkcjonowała pod nazwą BioGenerics, Inc. i zmieniła nazwę na Coherus BioSciences, Inc. w kwietniu 2012 roku. Coherus BioSciences, Inc. została założona w 2010 roku i ma siedzibę w Redwood City w Kalifornii.

Nazwa
Coherus Biosciences
CEO
Dennis Lanfear
Siedziba Redwood City, ca
Stany Zjednoczone
Strona internetowa
Sektor
Dobra podstawowe
Branża
Żywność
Debiut giełdowy
06.11.2014
Pracownicy 145

Symbole giełdowe

Giełda Symbol
NASDAQ
CHRS
Frankfurt
8C5.F
Düsseldorf
8C5.DU
SIX
8C5.SW
München
8C5.MU
🍪

Parqet  używa plików cookie. Dowiedz się więcej